# A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

> **NCT05446740** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 324 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** GSK4382276A Dose level 1
- **BIOLOGICAL:** GSK4382276A Dose level 2
- **BIOLOGICAL:** GSK4382276A Dose level 3
- **BIOLOGICAL:** GSK4382276A Dose level 4
- **BIOLOGICAL:** GSK4382276A Dose level 5
- **BIOLOGICAL:** GSK4382276A Dose level 6
- **BIOLOGICAL:** GSK4382276A Dose level 7
- **BIOLOGICAL:** GSK4382276A Dose level 8
- **BIOLOGICAL:** GSK4382276A Dose level 9
- **BIOLOGICAL:** GSK4382276A Dose level 10
- **COMBINATION_PRODUCT:** FDQ21A-NH
- **COMBINATION_PRODUCT:** FDQ22A-NH

## Key facts

- **NCT ID:** NCT05446740
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-09
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-03-26
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446740, "A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05446740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*